Oxford Asset Management’s Cytokinetics CYTK Stock Holding History

Oxford Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-156,783	Closed	-$1.78M	–	1801
2019 Q3	$1.78M	Sell	156,783 -61,991	-28%	-$778K	0.04%	615
2019 Q2	$2.46M	Buy	218,774 +22,656	+12%	+$218K	0.05%	556
2019 Q1	$1.59M	Buy	196,118 +95,337	+95%	+$701K	0.03%	695
2018 Q4	$637K	Buy	+100,781	New	+$739K	0.02%	1088
2017 Q3	–	Sell	-134,002	Closed	-$1.62M	–	1559
2017 Q2	$1.62M	Sell	134,002 -59,866	-31%	-$832K	0.03%	706
2017 Q1	$2.49M	Buy	+193,868	New	+$2.27M	0.06%	367
2016 Q1	–	Sell	-147,812	Closed	-$1.55M	–	821
2015 Q4	$1.55M	Sell	147,812 -254,296	-63%	-$2.49M	0.04%	443
2015 Q3	$2.69M	Buy	402,108 +209,421	+109%	+$1.43M	0.08%	244
2015 Q2	$1.29M	Buy	192,687 +57,975	+43%	+$380K	0.04%	415
2015 Q1	$913K	Buy	134,712 +36,632	+37%	+$274K	0.02%	475
2014 Q4	$722K	Buy	+98,080	New	+$421K	0.02%	520
2014 Q2	–	Sell	-98,132	Closed	-$932K	–	714
2014 Q1	$932K	Buy	+98,132	New	+$888K	0.03%	462

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Oxford Asset Management's CYTK Position: Q4 2019 in Review

Oxford Asset Management sold out of Cytokinetics (CYTK) in Q4 2019, closing a stake of 156,783 shares — an estimated $1.78M sold.

Oxford Asset Management first reported a position in CYTK in Q1 2014 and held it in 12 quarters. The position peaked at $2.69M in Q3 2015. 142 funds tracked by Wall St. Rank hold CYTK as of Q4 2019.

Oxford Asset Management reported no remaining Cytokinetics position as of Q4 2019 after selling out during the quarter.
Oxford Asset Management sold 156,783 Cytokinetics shares in Q4 2019, an estimated $1.78M.
Oxford Asset Management first reported a position in Cytokinetics in Q1 2014 and held it in 12 quarters.
Oxford Asset Management's Cytokinetics position peaked at $2.69M in Q3 2015.
142 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2019.

Based on Oxford Asset Management's 13F filing for Q4 2019, filed 13 Feb 2020.